Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION: ETX101 in Dravet Syndrome
NCT06283212Phase 2Active, not recruiting
- Sponsor
- Encoded Therapeutics
- Start
- May 2024
- Primary completion
- Oct 2030
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of etx101 in Dravet syndrome (4 cohorts), sponsored by Encoded Therapeutics. Primary endpoint: Monthly Countable Seizure Frequency. Started May 2024; status: active, not recruiting.
02
Drugs
etx101
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT06283212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06283212.